Metreleptin for Partial Lipodystrophy
(METRE-PL Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it mentions that patients should be on optimized stable therapy. This suggests you may need to continue your current treatment.
What data supports the effectiveness of the drug metreleptin for partial lipodystrophy?
How is the drug metreleptin unique for treating partial lipodystrophy?
Metreleptin is unique because it is specifically designed to replace leptin, a hormone that helps regulate fat and sugar levels in the body, which is often deficient in people with lipodystrophy. Unlike other treatments, it directly addresses the underlying hormone imbalance rather than just managing symptoms like high blood sugar or cholesterol.13567
What is the purpose of this trial?
This trial tests the safety and effectiveness of daily injections of metreleptin for people with Partial Lipodystrophy. The treatment aims to replace a missing hormone to help their bodies manage fat and sugar levels better. Metreleptin is approved by the United States Food and Drug Administration for the treatment of generalized forms of lipodystrophy and has shown improvement in many patients.
Eligibility Criteria
This trial is for individuals with a condition called Partial Lipodystrophy, specifically those diagnosed with Familial Partial Lipodystrophy (FPLD). It's not open to people who have already been treated with metreleptin.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily subcutaneous metreleptin or placebo for 12 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- metreleptin
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amryt Pharma
Lead Sponsor